$UTHRUNITED THERAPEUTICS Corp

📅 Upcoming

🕒 Recent(90d)

News

• Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
  CEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.
  biospace · 3h ago
• Varda raises $251M to leverage gravity in space for drug production
  Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules.
  biospace · 2d ago
• United Therapeutics' legal victory; BMS' Camzyos approved for kids
  Plus, news about United Therapeutics, MindRank, Novo, Atara Biotherapeutics, Pierre Fabre, Monte Rosa Therapeutics, Bristol Myers Squibb’s Camzyos and Skopos Bio. Nektar Therapeutics' shares drop 2…
  endpoints · 3d ago
• Roivant's pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
  Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, 'significantly exceeded expectations' in reducing pulmonary vascular resistance, according to analysts, and is progressing…
  biospace · 26d ago
• FDA extends review of Capricor cell therapy; Pain drug startup to go public
  The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
  biopharma_dive · 1mo ago
• Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein
  Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.
  fiercebiotech · 1mo ago
• STAT+: Moderna launches early trial of Ebola mRNA vaccine
  Novo and Lilly earnings are out, Aurora Therapeutics slashing staff, and more biotech news from The Readout
  stat · 2mo ago
• A PureTech startup banks $180M for a new IPF drug
  Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
  biopharma_dive · 3mo ago
• Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
  🧬 Vertex’s sickle cell gene therapy approved for kids: Casgevy may now be used to treat either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia patie…
  endpoints · 3mo ago
• BridgeBio gets funding for drug launch; United buys into cell therapy
  Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
  biopharma_dive · 3mo ago